Core One Labs Inc. (COOL) | WebDisclosure

Basculer en Français

8295	Companies
114850	Keywords
55292	Articles
62440	Press releases

Home
Companies
Core One Labs Inc.

BRIEF

published on 07/09/2024 at 01:20, 4 months 12 days ago

Core One Labs Enters into Loan Agreement with Right Season Investments

Loan Agreement Psychedelic Medicines Core One Labs Right Season Investments Psilocybin Production
BRIEF

published on 07/09/2024 at 01:20, 4 months 12 days ago

Core One Labs conclut un accord de prêt avec Right Season Investments

Accord De Prêt Laboratoires Core One Investissements De Bonne Saison Médicaments Psychédéliques Production De Psilocybine
PRESS RELEASE

published on 07/09/2024 at 01:15, 4 months 12 days ago

Core One Enters into Loan Agreement with Right Season Investments
Core One Labs Inc. secures CDN$300,000 loan from Right Season Investments Corp. for working capital. Company focuses on developing psychedelic medicines and innovative delivery systems

Loan Agreement Working Capital Core One Labs Inc. Psychedelic Medicines Biotechnology Research
PRESS RELEASE

published on 12/09/2023 at 00:55, 11 months 12 days ago

Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market
PRESS RELEASE

published on 12/02/2023 at 01:00, 11 months 19 days ago

Core One Labs’ Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer’s and Parkinson’s, Showing Potential to Outperform Current Treatment Methods
Core One Labs Inc. ('Core One') shares exciting results of Stage 2 animal model studies on Akome's five plant bioactives and DMT, demonstrating potential to outperform current treatment methods for Alzheimer's and Parkinson's. Research team to investigate elevated concentration levels of Bio-Compounds in further studies

Core One Labs Inc. Akome Stage 2 Animal Model Studies Bio-compounds Alzheimer's And Parkinson's
PRESS RELEASE

published on 08/05/2023 at 01:25, 1 year 3 months ago

Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's Disease
PRESS RELEASE

published on 08/02/2023 at 01:55, 1 year 3 months ago

Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass
PRESS RELEASE

published on 07/29/2023 at 01:25, 1 year 3 months ago

Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease
PRESS RELEASE

published on 07/22/2023 at 00:55, 1 year 3 months ago

Core One Labs Enters into Letter of Intent for First Sale of Its Psychedelic Compounds
PRESS RELEASE

published on 07/12/2023 at 01:25, 1 year 4 months ago

Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin

Accesswire

Published on 11/21/2024 at 11:30, 27 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 1 hour 54 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 1 hour 57 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 2 hours 57 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 11 hours 22 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 11:30, 27 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 11:01, 56 minutes ago

Original-Research: SMT Scharf AG (von Montega AG): Kaufen
Published on 11/21/2024 at 11:00, 57 minutes ago

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
Published on 11/21/2024 at 10:56, 1 hour ago

ABO Energy closes sale for two Battery Projects in South Africa
Published on 11/21/2024 at 10:30, 1 hour 27 minutes ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024

Les Echos

Published on 11/21/2024 at 06:58, 4 hours 59 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 59 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 59 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 15 hours 50 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 16 hours 37 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE